Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Celgene Corporation : Celgene's Profits Fall, But Focus Remains on Pipeline

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/24/2013 | 07:47pm CET

--Celgene's Q4 net falls, while revenues rise

--FDA approval decision for multiple myeloma drug Pomalyst expected in February

--Celgene shares down 2.4% to $97.64 so far this week as investors take profits

(Updates throughout adding details and analyst comment.)

 
   By Joseph Walker and Melodie Warner 
 

Celgene Corp.'s (CELG) fourth-quarter earnings fell 36% as restructuring costs and other special items hurt the drug maker's margins and masked its increased revenue.

The results had been expected since the Summit, N.J., company pre-announced full-year results for 2012 and 2013 guidance at an investor meeting earlier this month.

Celgene's revenues jumped 13% to $1.45 billion in the quarter, largely on the strength of its core blood-cancer drug franchise, which includes the blockbuster Revlimid treatment.

However, investor attention has been focused on the company's late-stage product pipeline, which includes what Celgene says are three "potential blockbusters" that would expand the company's portfolio into new disease areas.

The first of those drugs likely to reach the market is Pomalyst, a treatment for the patients with relapsed multiple myeloma, a bone marrow cancer. The U.S. Food and Drug Administration is scheduled to make an approval decision by Feb. 10. Celgene said it would launch the drug shortly after approval.

"Our commercial and medical affairs teams are ready to launch and support the thousands of patients who have exhausted all existing myeloma therapies," Celgene Executive Vice President Mark Alles said. "Successfully launching Pomalyst is a major corporate objective and we are ready."

Celgene shares fell 0.6% to $97.64, and are down 2.4% so far this week as investors take profits. Even with the recent slide, the stock has soared 24% in 2013, as investors have placed a high premium on the company's pipeline.

Celgene also plans to seek FDA approval for apremilast, a treatment for the skin disease Psoriasis, and its cancer drug Abraxane for patients with pancreatic cancer this year. Both drugs are projected to be generate billions of dollars annually for Celgene.

The new drugs are part of Celgene's strategy to expand beyond its core hematology franchise and build out new product lines in cancer to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $263.1 million, or 61 cents a share, down from $410.2 million, or 91 cents, a year earlier. Excluding items such as stock-based compensation, acquisition and restructuring costs, adjusted per-share earnings rose to $1.32 from $1.05 a year ago.

Analysts polled by Thomson Reuters had forecast earnings of $1.31 a share on revenue of $1.46 billion.

Revlimid sales jumped 17% to $1 billion, while Vidaza sales climbed 14% to $216 million.

Gross margin fell to 22.2% from 31.5% as costs rose because of preparations for the launches of Abraxane for non-small-cell lung cancer and Pomalyst. Abraxane received FDA approval for that indication in October.

Write to Joseph Walker at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
02/17CELGENE : OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in..
PU
02/17CELGENE : OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in..
BU
02/17CELGENE : OTEZLA (Apremilast) Phase II Data Showed Clinically Meaningful Improve..
AQ
02/16CELGENE : Announces Additional $5 Billion Share Repurchase Authorization
AQ
02/16AGIOS PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2017 Financial Resu..
AQ
02/16Celgene Spinout Celularity Raises $250 Million To Develop Placental Cells To ..
AQ
02/15Celularity unveils size of series A
AQ
02/15CELGENE CORPORATION : Commences Tender Offer for Juno Therapeutics, Inc.
AQ
02/15CELGENE : Studies from Celgene Yield New Data on Medicinal Chemistry
AQ
02/15RESEARCHERS FROM CELGENE REPORT NEW : Discovery...
AQ
More news
News from SeekingAlpha
02/17Venture capital deals of the week 
02/16Is Celgene A Growth Or A Value Stock? 
02/16Celgene's Otezla-Colitis Story; Implications For Other Biotechs 
02/16Celgene (CELG) Presents At Leerink Partners 7th Annual Global Healthcare Conf.. 
02/16Key events next week - healthcare 
Financials ($)
Sales 2018 14 810 M
EBIT 2018 8 539 M
Net income 2018 5 625 M
Finance 2018 346 M
Yield 2018 -
P/E ratio 2018 13,75
P/E ratio 2019 11,35
EV / Sales 2018 4,86x
EV / Sales 2019 3,92x
Capitalization 72 314 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 125 $
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman & Chief Executive Officer
Scott Andrew Smith President & Chief Operating Officer
Peter N. Kellogg Executive VP, Chief Financial & Accounting Officer
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-9.55%70 998
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572